Interactive iStopMM-Inspired Risk Calculator
This tool estimates progression risk for smoldering multiple myeloma (SMM) using commonly discussed clinical factors. It is designed for education and conversation prep—not diagnosis.
Examples may include specific abnormalities identified by FISH or similar testing.
Use “Yes” if your hematology team has documented meaningful upward biomarker trend.
What is the iStopMM risk calculator concept?
The iStopMM program (Iceland Screens, Treats, or Prevents Multiple Myeloma) helped expand how clinicians think about monoclonal gammopathies, early detection, and progression risk. In practical terms, an “iStopMM risk calculator” usually means using measurable lab and bone marrow features to estimate how likely a patient with smoldering myeloma is to progress toward active multiple myeloma over time.
Risk models are not fortune tellers. They are decision tools. Their value is in guiding how often to monitor, when to repeat imaging, and whether to discuss early treatment in selected high-risk situations.
How this page’s calculator works
This calculator uses five inputs commonly discussed in SMM risk conversations:
- M-protein level: Higher values may indicate larger clonal burden.
- Bone marrow plasma cell percentage: A direct measure of plasma cell infiltration.
- Free light chain (FLC) ratio: Reflects imbalance between involved and uninvolved chains.
- High-risk cytogenetics: Certain genomic findings can increase progression risk.
- Evolving pattern: Rising markers over time can matter as much as a single number.
It then generates a score and maps that score to a broad risk band (Low, Intermediate, High, or Very High) plus a rough 2-year progression estimate. Think of this as a conversation starter to help you ask better questions at your next hematology appointment.
Why trend data matters
One of the most important lessons from modern plasma cell disorder research is that direction matters. A patient with stable numbers can have a very different outlook from a patient with quickly rising markers—even if both snapshots look similar on one day.
How to interpret your result responsibly
- Low risk does not mean zero risk.
- Higher risk does not automatically mean immediate treatment.
- Clinical context (kidney function, anemia, imaging, symptoms) can change management.
- Different centers may use different validated scoring systems.
Questions to discuss with your hematologist
1) Which risk model are you using for me?
Ask whether your team uses IMWG 20-2-20, center-specific models, or research-based approaches influenced by iStopMM findings.
2) Do my numbers show a stable or evolving pattern?
Single values are useful, but change over time can be more clinically meaningful.
3) What monitoring schedule is appropriate?
Follow-up intervals may differ significantly between low-risk and high-risk groups. Clarify timing for labs, bone marrow reassessment, and imaging.
4) Should I be evaluated for a clinical trial?
For selected patients, clinical trials can provide access to early-intervention strategies and closer monitoring.
Limitations of any online risk tool
Online calculators cannot incorporate every nuance: lab assay differences, comorbidities, age-related factors, imaging interpretation, genetic detail, and physician judgment. They also do not diagnose CRAB criteria (hypercalcemia, renal impairment, anemia, bone lesions) or myeloma-defining events by themselves.
Use this tool to stay informed and organized, not to self-manage high-stakes decisions.
Bottom line
An iStopMM-style risk calculator can make complicated information easier to understand. The best use case is simple: prepare better questions, understand your own trend lines, and make decisions with a qualified hematology team. In this setting, data becomes empowering rather than overwhelming.